CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation

BACKGROUND: Claudin18.2 (CLDN18.2) is a tight junction protein that has been identified as a clinically proven target in gastric cancer. Stimulation of 4-1BB with agonistic antibodies is also a promising strategy for immunotherapy and 4-1BB(+) T cells were reported to be present within the tumor mic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jing, Wang, Zhengyi, Jiang, Wenqing, Zhang, Yanni, Meng, Zhen, Niu, Yanling, Sheng, Zhen, Chen, Chan, Liu, Xuejun, Chen, Xi, Liu, Chanjuan, Jia, Keren, Zhang, Cheng, Liao, Haiyan, Jung, Jaeho, Sung, Eunsil, Chung, Hyejin, Zhang, Jingwu Z., Zhu, Andrew X., Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410885/
https://www.ncbi.nlm.nih.gov/pubmed/37364935
http://dx.doi.org/10.1136/jitc-2023-006704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410885/
https://www.ncbi.nlm.nih.gov/pubmed/37364935
http://dx.doi.org/10.1136/jitc-2023-006704

Ejemplares similares